# Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

> **NCT01332929** · PHASE1 · COMPLETED · sponsor: **Centre Francois Baclesse** · enrollment: 21 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm to Brain

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01332929
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-09-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332929, "Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01332929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*